QDEL
QuidelOrtho Corp
Key Financials
Revenue
$2.7B
↓ 1.9%
Net Income
$-1131800000
↑ 44.8%
Operating Income
$-919200000
↑ 53.1%
Total Assets
$5.8B
↓ 10.2%
EPS (Diluted)
$-16.69
↑ 45.4%
Total Liabilities
$3.8B
↑ 11.9%
Cash & Equivalents
$169.8M
↑ 72.7%
Shareholders' Equity
$1.9B
↓ 35.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/13/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| SCHEDULE 13G/A | 8/5/2026 | View on SEC |
| 4 | 7/16/2026 | View on SEC |
| 3 | 7/15/2026 | View on SEC |
| S-8 | 7/13/2026 | View on SEC |
| SCHEDULE 13G | 7/8/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | QDEL |
| Company Name | QuidelOrtho Corp |
| CIK | 1906324 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 0101 |
| Phone | (858) 552-1100 |